CLINICAL TRIALS PROFILE FOR CHIGLITAZAR
✉ Email this page to a colleague
Clinical Trials for Chiglitazar
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02121717 ↗ | Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients | Completed | Chipscreen Biosciences, Ltd. | Phase 3 | The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo. |
| NCT02173457 ↗ | Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients | Completed | Chipscreen Biosciences, Ltd. | Phase 3 | The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with Sitagliptin. |
| NCT04807348 ↗ | Chiglitazar Added to Metformin for Type 2 Diabetes | Recruiting | Chipscreen Biosciences, Ltd. | Phase 3 | The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy. |
| NCT05193916 ↗ | Chiglitazar for NASH | Not yet recruiting | Chipscreen Biosciences, Ltd. | Phase 2 | This study is a non-invasive exploratory phase II trial. Among patients who were clinically diagnosed as non-alcoholic steatohepatitis (NASH) with liver fibrosis accompanied by elevated triglycerides (TG) and insulin resistance, the efficacy and safety of chiglitazar sodium tablets 48mg , 64mg or placebo qd for 18 weeks were observed. The result will provide support for future clinical studies of Chiglitazar Sodium in the treatment of NASH. |
| NCT05515445 ↗ | Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function | Not yet recruiting | Chipscreen Biosciences, Ltd. | Phase 1 | This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with varying degrees of hepatic impairment compared to subjects with normal hepatic function. |
| NCT05515458 ↗ | Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function | Not yet recruiting | Chipscreen Biosciences, Ltd. | Phase 1 | This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with renal impairment compared to subjects with normal renal function. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Chiglitazar
Condition Name
Clinical Trial Locations for Chiglitazar
Clinical Trial Progress for Chiglitazar
Clinical Trial Phase
Clinical Trial Sponsors for Chiglitazar
Sponsor Name
